These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36533099)

  • 1. Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis.
    Tillett W; Coates LC; Kiri S; Taieb V; Willems D; Mease PJ
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221140846. PubMed ID: 36533099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis.
    Rudwaleit M; Machado PM; Taieb V; de Peyrecave N; Hoepken B; Gensler LS
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231189079. PubMed ID: 37663034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis.
    Osterhaus JT; Purcaru O
    Arthritis Res Ther; 2014 Jul; 16(4):R140. PubMed ID: 24996416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.
    Kavanaugh A; Gladman D; van der Heijde D; Purcaru O; Mease P
    Ann Rheum Dis; 2015 Jan; 74(1):44-51. PubMed ID: 24942382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.
    van Vollenhoven RF; Felson D; Strand V; Weinblatt ME; Luijtens K; Keystone EC
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):128-34. PubMed ID: 20799264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
    Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
    Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study.
    van der Heijde D; Braun J; Rudwaleit M; Purcaru O; Kavanaugh AF
    RMD Open; 2018; 4(1):e000659. PubMed ID: 29670761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
    Fleischmann R; Vencovsky J; van Vollenhoven RF; Borenstein D; Box J; Coteur G; Goel N; Brezinschek HP; Innes A; Strand V
    Ann Rheum Dis; 2009 Jun; 68(6):805-11. PubMed ID: 19015206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L; Lapadula G; Mathieu A
    BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
    Iannone F; Semeraro A; Carlino G; Santo L; Bucci R; Quarta L; Maruotti N; Zuccaro C; Marsico A; Falappone PCF; Mazzotta D; Cantatore FP; Muratore M; Lapadula G
    Clin Drug Investig; 2019 Jun; 39(6):565-575. PubMed ID: 30941736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study.
    Westhovens R; Ravelingien I; Vandevyvere K; Pansar I; Purcaru O; Kumke T; Gyselbrecht L
    Acta Clin Belg; 2019 Oct; 74(5):342-350. PubMed ID: 30160189
    [No Abstract]   [Full Text] [Related]  

  • 13. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Keystone E; Heijde Dv; Mason D; Landewé R; Vollenhoven RV; Combe B; Emery P; Strand V; Mease P; Desai C; Pavelka K
    Arthritis Rheum; 2008 Nov; 58(11):3319-29. PubMed ID: 18975346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
    Smolen J; Landewé RB; Mease P; Brzezicki J; Mason D; Luijtens K; van Vollenhoven RF; Kavanaugh A; Schiff M; Burmester GR; Strand V; Vencovsky J; van der Heijde D
    Ann Rheum Dis; 2009 Jun; 68(6):797-804. PubMed ID: 19015207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with longstanding pPatients with longstanding psoriatic arthritis can achieve DAPSA remission or low disease activity and it correlates to better functional outcomes: results from a Latin-American real-life cohort.
    Cruz LV; Farani JB; Costa JR; de Andrade Águas JV; Ruschel B; de Almeida Menegat F; Gasparin AA; Brenol CV; Kohem CL; Bessa A; Forestiero F; Thies F; Palominos PE
    Adv Rheumatol; 2024 Jan; 64(1):3. PubMed ID: 38167571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
    Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
    Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis.
    Ogdie A; Gladman DD; Coates LC; Pournara E; Parikh B; Mease PJ
    Rheumatol Ther; 2023 Aug; 10(4):849-860. PubMed ID: 37148474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study.
    Bessette L; Haraoui B; Chow A; Fortin I; Dixit S; Khraishi M; Haaland D; Elmoufti S; Staelens F; Bogatyreva I; Syrotuik J; Shaikh S
    Ther Adv Musculoskelet Dis; 2019; 11():1759720X19831151. PubMed ID: 30858896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
    Coates LC; Nash P; Kvien TK; Gossec L; Mease PJ; Rasouliyan L; Pricop L; Jugl SM; Gandhi KK; Gaillez C; Smolen JS
    Semin Arthritis Rheum; 2020 Aug; 50(4):709-718. PubMed ID: 32521325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.